• Who We Serve
    • Hospitals
    • Community Health Centers
    • Contract Pharmacies
  • Solutions
    • Split Billing
    • CompliancePlus
    • Contract Pharmacy
    • Specialty Contract Pharmacy
    • Enterprise Backbone
  • About RxS
    • Company Overview
    • Executive Leadership
    • Board of Directors
  • News & Events
    • News
      • Blog
      • Clinical Insights
      • 340B Insider
      • Press Releases
    • Events
  • Connect With Us
    • Contact Us
    • Contact Support
  • Contact Support
  • Portal Login
  • Contact Support
  • Portal Login
  • Who We Serve
    • Hospitals
    • Community Health Centers
    • Contract Pharmacies
  • Solutions
    • Split Billing
    • CompliancePlus
    • Contract Pharmacy
    • Specialty Contract Pharmacy
    • Enterprise Backbone
  • About RxS
    • Company Overview
    • Executive Leadership
    • Board of Directors
  • News & Events
    • News
      • Blog
      • Clinical Insights
      • 340B Insider
      • Press Releases
    • Events
  • Connect With Us
    • Contact Us
    • Contact Support

HHS-OIG Criticizes 340B Drug Discount Program

    HHS-OIG Criticizes 340B Drug Discount Program

    Posted on February 14, 2014 by Tim Vroman - News

    Posted By Theresa C. Carnegie on February 11th, 2014Posted in Hospitals & Health Systems, Payors & PBMs, Pharma & Medical Devices, Pharmacies, State & Federal Audits, Investigations & Litigation

    Written by:  Ellyn L. Sternfield

    I recently posted that 2014 is expected to be a year of major developments in the 340B Drug Discount Program, with HRSA receiving enhanced funding, stepping up audit activity, and drafting regulations in response to criticism from multiple industry stakeholders. While those regulations are under development, the Office of Inspector General for the U.S. Department of Health and Human Services (OIG) has added its criticism to the mix.

    View Details

Categories

  • 340B Insider
  • Blog
  • Clinical Insights
  • Events
  • News
  • Press Releases

Archives

What clients say about RxStrategies:

  • "Due to RxStrategies' comprehensive solutions specifically for FQHCs to manage a compliant 340B program, our available discounts from the 340B program tripled in the rural areas where we operate in partnership with contract pharmacies."

  • "Communication throughout the transition process from another TPA was stellar. The RxStrategies team was there for us at a moment’s notice."

  • "The exemplary customer service RxStrategies' sales department and account managers provide is a key component of our strong partnership."

  • Who We Serve
  • Solutions
  • About RxS
  • News
  • Events
  • Contact Us
  • Contact Support
  • Portal Login

Want to receive updates straight to your inbox?

Sign up
© 2021 RxStrategies, Inc. All Rights Reserved. Privacy Statement